Myeloproliferative Neoplasms (MPNs) [Excluding CML]

Primary Myelofibrosis (PMF)

- Previously enrolled in HEMMPD0020 or HEMMPD0018
- HEMMPD0031 Phase II Luspatercept (ACE-536) in Myeloproliferative Neoplasm-Associated Myelofibrosis & Anemia +/-
  - PI: Goliib Celgene
- HEMMPD0030 Phase II Pacritinib in Myeloproliferative Disorders Previously Treated with Ruxolitinib
  - PI: Goliib CTI Biopharma

Aggressive Systemic Mastocytosis/ Mast Cell Leukemia

- CD30-

Chronic Neutrophilic Leukemia (CML) and Atypical Chronic Myeloid Leukemia (CML)

- HEMMPD0022 Phase II Prospective Evaluation of Ruxolitinib Efficacy for CML/aCML Patients with Mutation of CS3FR
  - PI: Goliib Incyte Corporation
- HEMMPD0028 Phase II INCB054828 in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
  - PI: Goliib OHSU Knight Cancer Center

FGFR1 Rearrangement

- HEMMPD0035 Phase II Ruxolitinib in Idiopathic Hypereosinophilic Syndrome & Primary Eosinophilic Disorders
  - PI: Goliib Pending

HEMMPD0034 Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis
  - Pt: Goliib Pending

1st Priority

HEMMPD0027 Phase I BLU-285 in Advanced Systemic Mastocytosis (advSM) & Relapsed/Refractory Myeloid Malignancies
  - Pt: Goliib Blueprint Medicines Corp

2nd Priority

HEMMPD0029 Phase I DCC-2618 in Advanced Malignancies
  - Pt: Goliib Deciphera Pharmaceuticals

3rd Priority

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold